ResMed (NYSE:RMD), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst ...

$60,000 of RESMED CORP. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Issues related to medical devices and ...

StockNews.com cut shares of ResMed (NYSE:RMD – Free Report) from a buy rating to a hold rating in a research note published on Friday morning. Several other equities analysts have also issued reports ...

LOS ANGELES, Feb. 12, 2025 /PRNewswire/ -- Triller is thrilled to announce its participation in a bell ringing ceremony at NASDAQ on February 18, 2025, at 9:30AM ET. This significant event marks ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth in revenue and profitability. The great quarter was driven by high ...